CN110183378A - A kind of derivative and its process for catalytic synthesis of niacinamide - Google Patents
A kind of derivative and its process for catalytic synthesis of niacinamide Download PDFInfo
- Publication number
- CN110183378A CN110183378A CN201910595185.8A CN201910595185A CN110183378A CN 110183378 A CN110183378 A CN 110183378A CN 201910595185 A CN201910595185 A CN 201910595185A CN 110183378 A CN110183378 A CN 110183378A
- Authority
- CN
- China
- Prior art keywords
- formula
- derivative
- compound
- catalytic synthesis
- niacinamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 36
- 238000007036 catalytic synthesis reaction Methods 0.000 title claims abstract description 26
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title claims description 20
- 229960003966 nicotinamide Drugs 0.000 title claims description 7
- 235000005152 nicotinamide Nutrition 0.000 title claims description 7
- 239000011570 nicotinamide Substances 0.000 title claims description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 67
- 238000006243 chemical reaction Methods 0.000 claims abstract description 51
- 239000003446 ligand Substances 0.000 claims abstract description 22
- 239000003054 catalyst Substances 0.000 claims abstract description 19
- 239000010949 copper Substances 0.000 claims abstract description 11
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910052802 copper Inorganic materials 0.000 claims abstract description 9
- IXQYPXRYRSEMAA-UHFFFAOYSA-N n-(1,3-diphenylprop-2-enylidene)hydroxylamine Chemical compound C=1C=CC=CC=1C(=NO)C=CC1=CC=CC=C1 IXQYPXRYRSEMAA-UHFFFAOYSA-N 0.000 claims abstract description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 47
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 41
- RFKZUAOAYVHBOY-UHFFFAOYSA-M copper(1+);acetate Chemical compound [Cu+].CC([O-])=O RFKZUAOAYVHBOY-UHFFFAOYSA-M 0.000 claims description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 21
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 229910021595 Copper(I) iodide Inorganic materials 0.000 claims description 9
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 claims description 9
- -1 toluene Sulfonyl nitrine Chemical compound 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 6
- 238000010189 synthetic method Methods 0.000 claims description 5
- 230000035484 reaction time Effects 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 claims 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 claims 1
- WRLRISOTNFYPMU-UHFFFAOYSA-N [S].CC1=CC=CC=C1 Chemical compound [S].CC1=CC=CC=C1 WRLRISOTNFYPMU-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 235000011150 stannous chloride Nutrition 0.000 claims 1
- 239000001119 stannous chloride Substances 0.000 claims 1
- 150000005480 nicotinamides Chemical class 0.000 abstract description 7
- 150000002576 ketones Chemical class 0.000 abstract description 6
- 238000003756 stirring Methods 0.000 abstract description 6
- NDLIRBZKZSDGSO-UHFFFAOYSA-N tosyl azide Chemical compound CC1=CC=C(S(=O)(=O)[N-][N+]#N)C=C1 NDLIRBZKZSDGSO-UHFFFAOYSA-N 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 75
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
- 230000000052 comparative effect Effects 0.000 description 34
- 239000002904 solvent Substances 0.000 description 26
- 239000012043 crude product Substances 0.000 description 20
- 239000003208 petroleum Substances 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- WTDHULULXKLSOZ-UHFFFAOYSA-N hydroxylamine hydrochloride Substances Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000002585 base Substances 0.000 description 10
- 239000003480 eluent Substances 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 9
- 235000005513 chalcones Nutrition 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 8
- GRERKWAIZGIGIM-UHFFFAOYSA-N (1-benzyltriazol-4-yl)methanamine Chemical compound N1=NC(CN)=CN1CC1=CC=CC=C1 GRERKWAIZGIGIM-UHFFFAOYSA-N 0.000 description 6
- WKGZJBVXZWCZQC-UHFFFAOYSA-N 1-(1-benzyltriazol-4-yl)-n,n-bis[(1-benzyltriazol-4-yl)methyl]methanamine Chemical compound C=1N(CC=2C=CC=CC=2)N=NC=1CN(CC=1N=NN(CC=2C=CC=CC=2)C=1)CC(N=N1)=CN1CC1=CC=CC=C1 WKGZJBVXZWCZQC-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 6
- 229940045803 cuprous chloride Drugs 0.000 description 6
- 238000001308 synthesis method Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000000843 anti-fungal effect Effects 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical group [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- MTAODLNXWYIKSO-UHFFFAOYSA-N 2-fluoropyridine Chemical compound FC1=CC=CC=N1 MTAODLNXWYIKSO-UHFFFAOYSA-N 0.000 description 1
- CCZWSTFVHJPCEM-UHFFFAOYSA-N 2-iodopyridine Chemical compound IC1=CC=CC=N1 CCZWSTFVHJPCEM-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical class N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- SBTSVTLGWRLWOD-UHFFFAOYSA-L copper(ii) triflate Chemical compound [Cu+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F SBTSVTLGWRLWOD-UHFFFAOYSA-L 0.000 description 1
- ZKXWKVVCCTZOLD-FDGPNNRMSA-N copper;(z)-4-hydroxypent-3-en-2-one Chemical compound [Cu].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O ZKXWKVVCCTZOLD-FDGPNNRMSA-N 0.000 description 1
- JIDMEYQIXXJQCC-UHFFFAOYSA-L copper;2,2,2-trifluoroacetate Chemical compound [Cu+2].[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F JIDMEYQIXXJQCC-UHFFFAOYSA-L 0.000 description 1
- ZKXWKVVCCTZOLD-UHFFFAOYSA-N copper;4-hydroxypent-3-en-2-one Chemical compound [Cu].CC(O)=CC(C)=O.CC(O)=CC(C)=O ZKXWKVVCCTZOLD-UHFFFAOYSA-N 0.000 description 1
- FDIRIOAEXPIEBL-UHFFFAOYSA-L copper;thiophene-2-carboxylate Chemical compound [Cu+2].[O-]C(=O)C1=CC=CS1.[O-]C(=O)C1=CC=CS1 FDIRIOAEXPIEBL-UHFFFAOYSA-L 0.000 description 1
- NIPZPLSTRCTEND-UHFFFAOYSA-N copper;thiophene-2-carboxylic acid Chemical compound [Cu].OC(=O)C1=CC=CS1 NIPZPLSTRCTEND-UHFFFAOYSA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007040 multi-step synthesis reaction Methods 0.000 description 1
- CYQYCASVINMDFD-UHFFFAOYSA-N n,n-ditert-butyl-2-methylpropan-2-amine Chemical compound CC(C)(C)N(C(C)(C)C)C(C)(C)C CYQYCASVINMDFD-UHFFFAOYSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- STWNGMSGPBZFMX-UHFFFAOYSA-N pyridine-3-carboxamide Chemical class NC(=O)C1=CC=CN=C1.NC(=O)C1=CC=CN=C1 STWNGMSGPBZFMX-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- HSVFKFNNMLUVEY-UHFFFAOYSA-N sulfuryl diazide Chemical compound [N-]=[N+]=NS(=O)(=O)N=[N+]=[N-] HSVFKFNNMLUVEY-UHFFFAOYSA-N 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
Abstract
本发明提供了一种烟酰胺的衍生物及其催化合成方法,所述衍生物为2‑甲基‑4,6‑二苯基‑N‑对甲苯磺酰基烟酰胺,其结构如式(I)所示;其催化合成方法包括以下步骤:在铜催化剂和配体的存在下,如式(Ⅱ)所示的查耳酮肟、如式(Ⅲ)所示的对甲苯磺酰基叠氮与如式(Ⅳ)所示的3‑丁炔‑2酮搅拌反应,从而得到如式(I)所示的化合物,该方法反应条件简单,通过催化剂和配体的合适选择与组合,从而可以高产率得到目的产物,具有很高的理论研究价值和应用价值。 The present invention provides a derivative of nicotinamide and a catalytic synthesis method thereof. The derivative is 2-methyl-4,6-diphenyl-N-p-toluenesulfonyl nicotinamide, and its structure is as shown in formula (I ); its catalytic synthesis method comprises the following steps: in the presence of a copper catalyst and a ligand, chalcone oxime as shown in formula (II), p-toluenesulfonyl azide as shown in formula (III) and 3-butyne-2 ketone stirring reaction as shown in formula (IV), thereby obtains the compound shown in formula (I), this method reaction condition is simple, through the suitable selection and combination of catalyst and ligand, thereby can high yield The target product can be obtained with high efficiency, which has high theoretical research value and application value.
Description
技术领域technical field
本发明涉及有机化学合成领域,具体涉及一种烟酰胺的衍生物及其催化合成方法。The invention relates to the field of organic chemical synthesis, in particular to a derivative of nicotinamide and a catalytic synthesis method thereof.
背景技术Background technique
含有吡啶杂环的烟酰胺衍生物是一类非常重要的有机分子,是辅酶以及药物中的重要结构。例如烟酰胺为辅酶I(烟酰胺腺嘌呤二核苷酸)、辅酶II(烟酰胺腺嘌呤二核苷酸磷酸)、磷酸核糖转移酶等的组成部分,在生物体中起到氧化还原、抗炎、抗菌、抗衰老等作用。Nicotinamide derivatives containing pyridine heterocycles are a very important class of organic molecules, and are important structures in coenzymes and drugs. For example, nicotinamide is a component of coenzyme I (nicotinamide adenine dinucleotide), coenzyme II (nicotinamide adenine dinucleotide phosphate), phosphoribosyltransferase, etc. Inflammation, antibacterial, anti-aging and other effects.
烟酰胺衍生物在抗真菌方面具有特异性,它能特异性的抑制介导组蛋白H3上56位赖氨酸去乙酰化酶的活性从而产生抗真菌作用,对于皮肤的致病真菌也有显著的抑制作用。鉴于烟酰胺衍生物广泛且安全的药理学作用,并且现有的资料中,烟酰胺的结构相对单一,种类较少,抗真菌的药效有待进一步提高,我们期待通过设计催化合成方法,开发新型的,抗真菌药效更高的烟酰胺衍生物。Niacinamide derivatives are specific in antifungal, it can specifically inhibit the activity of mediating 56-position lysine deacetylase on histone H3 to produce antifungal effect, and it also has a significant effect on pathogenic fungi of the skin inhibition. In view of the extensive and safe pharmacological effects of nicotinamide derivatives, and in the existing data, the structure of nicotinamide is relatively single and there are few types, and the antifungal efficacy needs to be further improved. We look forward to the design of catalytic synthesis methods to develop new , a derivative of niacinamide with higher antifungal efficacy.
Allais,C.等人(“Metal-free multicomponent syntheses of pyridines”,Chem.Rev.2014,114,10829-10868.)公开了由β-羰基酰胺衍生物、另一羰基化合物、醛、铵为起始原料经Hantzsch吡啶合成法合成烟酰胺衍生物。该方法先在乙酸、柠檬酸、对甲苯磺酰酸等酸的作用下合成二氢吡啶,再外加入亚硝酸或铁氰化钾等氧化剂进行氧化得到目标产物,经多步合成,操作繁琐。Allais, C. et al. ("Metal-free multicomponent syntheses of pyridines", Chem. Rev. 2014, 114, 10829-10868.) disclosed that a β-carbonyl amide derivative, another carbonyl compound, an aldehyde, an ammonium Niacinamide derivatives were synthesized from starting materials by Hantzsch pyridine synthesis. The method first synthesizes dihydropyridine under the action of acids such as acetic acid, citric acid, and p-toluenesulfonyl acid, and then adds oxidants such as nitrous acid or potassium ferricyanide to oxidize to obtain the target product. The multi-step synthesis is cumbersome to operate.
Khan,M.N.等人(“A simple and efficient method for the facile access ofhighly functionalized pyridines and their fluorescence property studies”,RSCAdv.2012,2,12305-12314.)公开了由丙二腈衍生物为起始原料先合成3-氰基吡啶,进一步水解氰基得到烟酰胺衍生物。该方法也需要多步进行,且在水解过程中存在反应条件苛刻、官能团兼容性差和对环境不友好等缺点。Khan, M.N. et al. ("A simple and efficient method for the facile access of highly functionalized pyridines and their fluorescence property studies", RSCAdv.2012, 2, 12305-12314.) disclosed that malononitrile derivatives were used as starting materials Synthesize 3-cyanopyridine, and further hydrolyze the cyano group to obtain nicotinamide derivatives. This method also needs to be carried out in multiple steps, and there are disadvantages such as harsh reaction conditions, poor functional group compatibility, and environmental unfriendliness during the hydrolysis process.
近几年,以酮肟或者酮肟酯为起始原料合成多取代吡啶的技术是研究的热点(“Vessally,E.;Saeidian,H.;Hosseinian,A.;Edjlali,L.;Bekhradnia,A.A review onsynthetic applications of oxime esters.Curr.Org.Chem.2017,21,249-271.)。该方法使用一价铜源试剂催化,在原料中引入具有氧化性的肟,不仅可提供胺源,且在反应中氧化生成的二氢吡啶,实现了一锅法的合成。但由于β-羰基酰胺衍生物在此反应中活性低,导致产物产率低,其复杂的结构需要提前合成等原因,限制了产物的多样性。因此,发展一种原料易得、条件简单、高效的一锅法合成烟酰胺衍生物是十分必要的。In recent years, the technology of synthesizing polysubstituted pyridines with ketoxime or ketoxime ester as the starting material has been a research hotspot (“Vessally, E.; Saeidian, H.; Hosseinian, A.; Edjlali, L.; Bekhradnia, A.A. review onsynthetic applications of oxime esters.Curr.Org.Chem.2017,21,249-271.). This method is catalyzed by a monovalent copper source reagent, and an oxidative oxime is introduced into the raw material, which not only provides an amine source, but also The dihydropyridine generated by the oxidation in medium realizes the synthesis of one-pot method. However, due to the low activity of β-carbonyl amide derivatives in this reaction, the product yield is low, and its complex structure needs to be synthesized in advance, which limits the product Therefore, it is necessary to develop a one-pot method for synthesizing nicotinamide derivatives with readily available raw materials, simple conditions and high efficiency.
如上所述,现有技术中已经公开了烟酰胺衍生物多种合成方法,但这些方法存在经多步处理合成、原料昂贵难获得,产物产率低等缺点,对于发展新的烟酰胺衍生物合成方法,仍存在必要,这也正是本发明得以完成的基础和动力所在。As mentioned above, a variety of synthetic methods of nicotinamide derivatives have been disclosed in the prior art, but these methods have the disadvantages of multi-step synthesis, expensive raw materials and difficult to obtain, and low product yields. Synthetic method still exists and is necessary, and this is just the foundation and power place that the present invention is accomplished.
发明内容Contents of the invention
本发明的目的在于提供一种烟酰胺(尼古酰胺)的衍生物及其催化合成方法,该衍生物为2-甲基-4,6-二苯基-N-对甲苯磺酰基烟酰胺化合物(C26H22N2O3S),反应条件简单,同时取得了良好的产率。The object of the present invention is to provide a derivative of nicotinamide (nicotinamide) and its catalytic synthesis method, the derivative is 2-methyl-4,6-diphenyl-N-p-toluenesulfonyl nicotinamide compound (C 26 H 22 N 2 O 3 S), the reaction conditions are simple, and a good yield has been obtained.
为实现以上目的,本发明通过以下技术方案予以实现:To achieve the above object, the present invention is achieved through the following technical solutions:
一种烟酰胺的衍生物,所述衍生物为2-甲基-4,6-二苯基-N-对甲苯磺酰基烟酰胺,其结构如式(I)所示:A derivative of nicotinamide, said derivative is 2-methyl-4,6-diphenyl-N-p-toluenesulfonyl nicotinamide, its structure is shown in formula (I):
本发明中如式(I)所示的烟酰胺衍生物化合物,即2-甲基-4,6-二苯基-N-对甲苯磺酰基烟酰胺化合物(C26H22N2O3S)的催化合成方法,包括以下步骤:在铜催化剂和配体的存在下,如式(Ⅱ)所示的查耳酮肟(式(II)化合物)、如式(Ⅲ)所示的对甲苯磺酰基叠氮(式(Ⅲ)化合物)与如式(Ⅳ)所示的3-丁炔-2酮(式(Ⅳ)化合物)搅拌反应,从而得到如式(I)所示的化合物(式(I)化合物)。In the present invention, the nicotinamide derivative compound represented by formula (I), that is, 2-methyl-4,6-diphenyl-N-p-toluenesulfonyl nicotinamide compound (C 26 H 22 N 2 O 3 S ) catalytic synthesis method, comprising the following steps: in the presence of a copper catalyst and a ligand, chalcone oxime (compound of formula (II)) as shown in formula (II), p-toluene as shown in formula (III) Sulfonyl azide (formula (Ⅲ) compound) and 3-butyn-2 ketone (formula (Ⅳ) compound) as shown in formula (Ⅳ) stirring reaction, thus obtain the compound (formula (Ⅳ) compound) as shown in formula (I) (I) compound).
在本发明的所述催化合成方法中,所述铜催化剂为醋酸铜(Cu(OAc)2)、氯化铜(CuCl2)、溴化铜(CuBr2)、乙酰丙酮铜(Cu(acac)2)、三氟乙酸铜(Cu(TFA)2)、碘化亚铜(CuI)、溴化亚铜(CuBr)、氯化亚铜(CuCl)、噻吩-2-甲酸铜(CuTc)、或醋酸亚铜(CuOAc)中的任意一种,优选为碘化亚铜(CuI)、氯化亚铜(CuCl)或醋酸亚铜(CuOAc),最优选为醋酸亚铜(CuOAc)。In the catalytic synthesis method of the present invention, the copper catalyst is copper acetate (Cu(OAc) 2 ), copper chloride (CuCl 2 ), copper bromide (CuBr 2 ), copper acetylacetonate (Cu(acac) 2 ), copper trifluoroacetate (Cu(TFA) 2 ), cuprous iodide (CuI), cuprous bromide (CuBr), cuprous chloride (CuCl), copper thiophene-2-carboxylate (CuTc), or Any one of cuprous acetate (CuOAc), preferably cuprous iodide (CuI), cuprous chloride (CuCl) or cuprous acetate (CuOAc), most preferably cuprous acetate (CuOAc).
在本发明的所述催化合成方法中,所述配体为乙腈(MeCN)、N,N-二甲基甲酰胺(DMF)、三乙胺(Et3N)、正三丁胺(nBu3N)、三叔丁胺(tBu3N)、2-氟吡啶(2-FPy)、2-氯吡啶(2-ClPy)、2-溴吡啶(2-BrPy)、2-碘吡啶(2-BrPy)、三[(1-苄基-1H-1,2,3-三唑-4-基)甲基]胺(TBTA)中的任意一种或者不加入配体,优选为三[(1-苄基-1H-1,2,3-三唑-4-基)甲基]胺(TBTA)、乙腈(MeCN)中的任意一种或者不加入配体(不加入配体时以乙腈为溶剂),最优选为三[(1-苄基-1H-1,2,3-三唑-4-基)甲基]胺(TBTA)。。In the catalytic synthesis method of the present invention, the ligands are acetonitrile (MeCN), N,N-dimethylformamide (DMF), triethylamine (Et 3 N), n-tributylamine ( n Bu 3 N), tri-tert-butylamine (tBu 3 N), 2-fluoropyridine (2- FPy ), 2-chloropyridine (2-ClPy), 2-bromopyridine (2-BrPy), 2-iodopyridine (2-BrPy ), any one of three [(1-benzyl-1H-1,2,3-triazol-4-yl) methyl] amine (TBTA) or no ligand, preferably three [(1- Any one of benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA), acetonitrile (MeCN) or no ligand (when no ligand is added, acetonitrile is used as solvent ), most preferably tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA). .
在本发明的所述催化合成方法中,式(II)化合物与催化剂、配体的摩尔比为1:0.05-0.4:0.1-2,例如可为1:0.1:0.1、1:0.2:0.2、1:0.25:0.5、1:0.2:1等。In the catalytic synthesis method of the present invention, the molar ratio of the compound of formula (II) to the catalyst and the ligand is 1:0.05-0.4:0.1-2, such as 1:0.1:0.1, 1:0.2:0.2, 1:0.25:0.5, 1:0.2:1, etc.
在本发明的所述催化合成方法中,式(II)化合物、式(III)化合物、式(IV)化合物的摩尔比为1:1-3:1-3,例如可为1:1:1、1:1.5:1.5或1:3:3。In the catalytic synthesis method of the present invention, the molar ratio of the compound of formula (II), the compound of formula (III) and the compound of formula (IV) is 1:1-3:1-3, for example, it can be 1:1:1 , 1:1.5:1.5 or 1:3:3.
在本发明的所述催化合成方法中,所述的有机溶剂可为乙醇(EtOH)、乙腈(MeCN)、四氢呋喃(THF)、N,N-二甲基甲酰胺(DMF)、N,N-二甲基乙酰胺(DMA)、氯苯、苯、二甲苯、N-甲基吡咯烷酮(NMP)中的任意一种,最优选为乙腈(MeCN)。In the catalytic synthesis method of the present invention, the organic solvent can be ethanol (EtOH), acetonitrile (MeCN), tetrahydrofuran (THF), N,N-dimethylformamide (DMF), N,N- Any one of dimethylacetamide (DMA), chlorobenzene, benzene, xylene, and N-methylpyrrolidone (NMP), most preferably acetonitrile (MeCN).
其中,MeCN既可作为反应溶剂,也可作为反应得以顺利进行的配体,如此不但可以简便操作,便于反应控制,而且后处理得以进一步简便化,从而更方便了整个反应的操作。Among them, MeCN can be used not only as a reaction solvent, but also as a ligand for the smooth progress of the reaction, which not only facilitates the operation and control of the reaction, but also facilitates the post-treatment, thus making the operation of the entire reaction more convenient.
在本发明的所述催化合成方法中,以毫摩尔计(mmol)计的所述如式(II)所示的化合物与以毫升(mL)计的所述溶剂的比为1:5-15,即每1毫摩尔计(mmol)所述式(II)化合物使用5-15毫升(mL)溶剂,具体比可为1:5、1:8、1:10、1:12或1:15。In the catalytic synthesis method of the present invention, the ratio of the compound represented by formula (II) in millimoles (mmol) to the solvent in milliliters (mL) is 1:5-15 , that is, the compound of formula (II) per 1 millimole (mmol) uses 5-15 milliliters (mL) of solvent, and the specific ratio can be 1:5, 1:8, 1:10, 1:12 or 1:15 .
在本发明的所述催化合成方法中,反应温度为25-80℃,例如可为25℃、40℃、60℃或80℃。反应时间为0.5-8小时,例如可为0.5小时、1小时、2小时、4小时或8小时。In the catalytic synthesis method of the present invention, the reaction temperature is 25-80°C, such as 25°C, 40°C, 60°C or 80°C. The reaction time is 0.5-8 hours, for example, it can be 0.5 hours, 1 hour, 2 hours, 4 hours or 8 hours.
在本发明的所述方法中,反应结束后的后处理可为萃取、浓缩、结晶、重结晶、柱层色谱提纯等中的任何一种处理手段或多种处理手段的组合。作为一种例举性的后处理手段,例如可为:反应完全后,将反应体系自然冷却至室温,减压蒸馏除去溶剂得粗产物,将粗产物过200-300目硅胶柱色谱层析,以乙酸乙酯和石油醚混合液为洗脱剂,其中乙酸乙酯与石油醚的体积比1:5-10,从而得到目标产物式(I)化合物。In the method of the present invention, the post-treatment after the reaction can be any one of extraction, concentration, crystallization, recrystallization, column chromatography purification, etc. or a combination of multiple treatment means. As an exemplary post-treatment means, for example, after the reaction is complete, the reaction system is naturally cooled to room temperature, and the solvent is distilled off under reduced pressure to obtain a crude product, and the crude product is subjected to 200-300 mesh silica gel column chromatography, A mixture of ethyl acetate and petroleum ether is used as the eluent, wherein the volume ratio of ethyl acetate to petroleum ether is 1:5-10, so as to obtain the compound of formula (I) as the target product.
在本发明的所述催化合成方法中,作为起始原料的式(III)化合物和式(IV)化合物可以直接购买。In the catalytic synthesis method of the present invention, the compounds of formula (III) and formula (IV) as starting materials can be purchased directly.
在本发明的所述催化合成方法中,作为起始原料的式(II)化合物的合成方法如下:在有机溶剂中,于碱存在下,如式(V)所示的查耳酮化合物(式(V)化合物)和如式(VI)所示的盐酸羟胺化合物(式(VI)化合物)搅拌反应,从而得到式(II)化合物。In the catalytic synthesis method of the present invention, the synthesis method of the compound of formula (II) as the starting material is as follows: in an organic solvent, in the presence of a base, the chalcone compound (formula (V) compound) and the hydroxylamine hydrochloride compound (formula (VI) compound) shown in formula (VI) are stirred and reacted, thereby obtaining the formula (II) compound.
在式(II)化合物的合成方法中,所述碱为吡啶、三乙胺、碳酸钾、乙醇钠、叔丁醇钾、氢氧化钠等中的任意一种,优选吡啶或三乙胺,最优选为吡啶。In the synthesis method of the compound of formula (II), the base is any one of pyridine, triethylamine, potassium carbonate, sodium ethylate, potassium tert-butoxide, sodium hydroxide, etc., preferably pyridine or triethylamine, most preferably Pyridine is preferred.
在式(II)化合物的合成方法中,所述有机溶剂为甲醇(MeOH)、乙醇(EtOH)、乙腈(MeCN)、N,N-二甲基甲酰胺(DMF)、N,N-二甲基乙酰胺(DMA)、氯苯、苯、二甲苯、二甲基亚砜(DMSO)、N-甲基吡咯烷酮(NMP)中的任意一种,优选甲醇(MeOH)或乙醇(EtOH);最优选为乙醇(EtOH)。In the synthesis method of the compound of formula (II), the organic solvent is methanol (MeOH), ethanol (EtOH), acetonitrile (MeCN), N,N-dimethylformamide (DMF), N,N-dimethyl Any one of methyl acetamide (DMA), chlorobenzene, benzene, xylene, dimethylsulfoxide (DMSO), N-methylpyrrolidone (NMP), preferably methanol (MeOH) or ethanol (EtOH); most Ethanol (EtOH) is preferred.
其中,所述有机溶剂的用量并没有特别的限定,例如可为便于反应进行和控制,以及便于后处理的量,本领域技术人员可根据常规技术手段进行合理的确定和选择。Wherein, the amount of the organic solvent is not particularly limited, for example, it may be an amount that is convenient for the reaction and control, and for post-treatment, and those skilled in the art can reasonably determine and select according to conventional technical means.
在式(II)化合物的合成方法中,式(V)化合物、式(VI)化合物、碱的摩尔比为1:1.5-4:2-6,例如可为1:1.5:2.5、1:2:3、1:2.5:4或1:3:6。In the synthesis method of the compound of formula (II), the molar ratio of the compound of formula (V), the compound of formula (VI), and the base is 1:1.5-4:2-6, for example, it can be 1:1.5:2.5, 1:2 :3, 1:2.5:4, or 1:3:6.
在式(II)化合物的合成方法中,反应温度为60-100℃,例如可为60℃、70℃、80℃或100℃。反应时间为4-12小时,例如可为4小时、8小时或12小时。In the synthesis method of the compound of formula (II), the reaction temperature is 60-100°C, for example, it can be 60°C, 70°C, 80°C or 100°C. The reaction time is 4-12 hours, for example, it can be 4 hours, 8 hours or 12 hours.
在所述式(II)化合物的合成方法中,反应完成后的后处理具体为:反应结束后,将反应体系自然冷却至室温,减压蒸馏除去溶剂得混合物,将混合物倒入1:1的水和乙酸乙酯中,萃取2-4次,收集有机相,用1mol/L的稀盐酸和饱和食盐水洗涤,MgSO4干燥,减压蒸馏旋干得到粗产品,将粗产物过200-300目硅胶柱色谱层析,以乙酸乙酯和石油醚混合液为洗脱剂,其中乙酸乙酯与石油醚的体积比1:5-10,从而得到目标产物式(II)化合物。In the synthesis method of the compound of formula (II), the post-treatment after the reaction is specifically as follows: after the reaction, the reaction system is naturally cooled to room temperature, and the solvent is removed by distillation under reduced pressure to obtain a mixture, and the mixture is poured into a 1:1 In water and ethyl acetate, extract 2-4 times, collect the organic phase, wash with 1mol/L dilute hydrochloric acid and saturated brine, dry over MgSO 4 , distill and spin-dry under reduced pressure to obtain the crude product, pass the crude product through 200-300 Silica gel column chromatography, using ethyl acetate and petroleum ether mixture as eluent, wherein the volume ratio of ethyl acetate and petroleum ether is 1:5-10, so as to obtain the target product formula (II) compound.
如上所述,本发明提供了式(I)化合物,以及提供了该化合物的合成方法,所述合成方法通过合适催化剂和配体的选择与协同作用,从而可得到式(I)化合物,反应条件简单,同时取得了良好的产率,为烟酰胺衍生物的制备提供了新的合成路线,在工业和科研上具有良好的应用价值和潜力。As mentioned above, the present invention provides a compound of formula (I) and a synthetic method of the compound. The synthetic method can obtain the compound of formula (I) through the selection and synergy of a suitable catalyst and ligand. The reaction conditions The method is simple and achieves good yield at the same time, provides a new synthetic route for the preparation of nicotinamide derivatives, and has good application value and potential in industry and scientific research.
具体实施方式Detailed ways
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are part of the present invention Examples, not all examples. Based on the embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without creative efforts fall within the protection scope of the present invention.
实施例1:Example 1:
向适量EtOH中,加入如式(V)所示的查耳酮、如式(VI)所示的盐酸羟胺和吡啶,升温至60℃,并在该温度下搅拌反应12小时;其中,如式(V)所示的查耳酮、如式(VI)所示的盐酸羟胺、吡啶的摩尔比为1:1.5:2.5。To an appropriate amount of EtOH, add chalcone shown in formula (V), hydroxylamine hydrochloride and pyridine shown in formula (VI), raise the temperature to 60°C, and stir the reaction at this temperature for 12 hours; wherein, as shown in formula The molar ratio of chalcone shown in (V), hydroxylamine hydrochloride shown in formula (VI), and pyridine is 1:1.5:2.5.
反应结束后,将反应体系自然冷却至室温,减压蒸馏除去溶剂得混合物,将混合物倒入1:1的水和乙酸乙酯中,萃取2-4次,收集有机相,用1mol/L的稀盐酸和饱和食盐水洗涤,MgSO4干燥,减压蒸馏旋干得到粗产品,将粗产物过200-300目硅胶柱色谱层析,以乙酸乙酯和石油醚混合液为洗脱剂,其中乙酸乙酯与石油醚的体积比1:5,从而得到为白色固体的式(II)化合物,熔点为112.3-114.4℃,产率为82.6%。After the reaction, the reaction system was naturally cooled to room temperature, and the solvent was distilled off under reduced pressure to obtain a mixture. The mixture was poured into 1:1 water and ethyl acetate, extracted 2-4 times, and the organic phase was collected. Wash with dilute hydrochloric acid and saturated brine, dry over MgSO 4 , distill under reduced pressure and spin dry to obtain the crude product, the crude product is subjected to 200-300 mesh silica gel column chromatography, with ethyl acetate and petroleum ether mixed solution as eluent, wherein The volume ratio of ethyl acetate to petroleum ether was 1:5 to obtain the compound of formula (II) as a white solid with a melting point of 112.3-114.4° C. and a yield of 82.6%.
实施例2:Example 2:
反应式同实施例1,具体操作为:Reaction formula is with embodiment 1, and concrete operation is:
向适量EtOH中,加入如式(V)所示的查耳酮、如式(VI)所示的盐酸羟胺和吡啶,升温至70℃,并在该温度下搅拌反应8小时;其中,其中,如式(V)所示的查耳酮、如式(VI)所示的盐酸羟胺、吡啶的摩尔比为1:2:3。To an appropriate amount of EtOH, add chalcone represented by formula (V), hydroxylamine hydrochloride and pyridine represented by formula (VI), raise the temperature to 70°C, and stir the reaction at this temperature for 8 hours; wherein, wherein, The molar ratio of chalcone represented by formula (V), hydroxylamine hydrochloride represented by formula (VI), and pyridine is 1:2:3.
反应结束后,将反应体系自然冷却至室温,减压蒸馏除去溶剂得混合物,将混合物倒入1:1的水和乙酸乙酯中,萃取2-4次,收集有机相,用1mol/L的稀盐酸和饱和食盐水洗涤,MgSO4干燥,减压蒸馏旋干得到粗产品,将粗产物过200-300目硅胶柱色谱层析,以乙酸乙酯和石油醚混合液为洗脱剂,其中乙酸乙酯与石油醚的体积比1:8,从而得到为白色固体的式(II)化合物,熔点同实施例1,产率为84.5%。After the reaction, the reaction system was naturally cooled to room temperature, and the solvent was distilled off under reduced pressure to obtain a mixture. The mixture was poured into 1:1 water and ethyl acetate, extracted 2-4 times, and the organic phase was collected. Wash with dilute hydrochloric acid and saturated brine, dry over MgSO 4 , distill under reduced pressure and spin dry to obtain the crude product, the crude product is subjected to 200-300 mesh silica gel column chromatography, with ethyl acetate and petroleum ether mixed solution as eluent, wherein The volume ratio of ethyl acetate to petroleum ether was 1:8, thereby obtaining the compound of formula (II) as a white solid, the melting point of which was the same as that of Example 1, and the yield was 84.5%.
实施例3:Example 3:
反应式同实施例1,具体操作为:Reaction formula is with embodiment 1, and concrete operation is:
向适量EtOH中,加入如式(V)所示的查耳酮、如式(VI)所示的盐酸羟胺和吡啶,升温至80℃,并在该温度下搅拌反应6小时;其中,如式(V)所示的查耳酮、如式(VI)所示的盐酸羟胺、吡啶的摩尔比为1:2.5:4。To an appropriate amount of EtOH, add chalcone shown in formula (V), hydroxylamine hydrochloride and pyridine shown in formula (VI), raise the temperature to 80°C, and stir the reaction at this temperature for 6 hours; wherein, as shown in formula The molar ratio of chalcone shown in (V), hydroxylamine hydrochloride shown in formula (VI), and pyridine is 1:2.5:4.
反应结束后,将反应体系自然冷却至室温,减压蒸馏除去溶剂得混合物,将混合物倒入1:1的水和乙酸乙酯中,萃取2-4次,收集有机相,用1mol/L的稀盐酸和饱和食盐水洗涤,MgSO4干燥,减压蒸馏旋干得到粗产品,将粗产物过200-300目硅胶柱色谱层析,以乙酸乙酯和石油醚混合液为洗脱剂,其中乙酸乙酯与石油醚的体积比1:7,从而得到为白色固体的式(II)化合物,熔点同实施例1,产率为80.7%。After the reaction, the reaction system was naturally cooled to room temperature, and the solvent was distilled off under reduced pressure to obtain a mixture. The mixture was poured into 1:1 water and ethyl acetate, extracted 2-4 times, and the organic phase was collected. Wash with dilute hydrochloric acid and saturated brine, dry over MgSO 4 , distill under reduced pressure and spin dry to obtain the crude product, the crude product is subjected to 200-300 mesh silica gel column chromatography, with ethyl acetate and petroleum ether mixed solution as eluent, wherein The volume ratio of ethyl acetate to petroleum ether was 1:7 to obtain the compound of formula (II) as a white solid, the melting point of which was the same as that of Example 1, and the yield was 80.7%.
实施例4:Example 4:
反应式同实施例1,具体操作为:Reaction formula is with embodiment 1, and concrete operation is:
向适量EtOH中,加入如式(V)所示的查耳酮、如式(VI)所示的盐酸羟胺和吡啶,升温至80℃,并在该温度下搅拌反应4小时;其中,如式(V)所示的查耳酮、如式(VI)所示的盐酸羟胺、吡啶的摩尔比为1:3:6。To an appropriate amount of EtOH, add chalcone shown in formula (V), hydroxylamine hydrochloride and pyridine shown in formula (VI), raise the temperature to 80°C, and stir the reaction at this temperature for 4 hours; wherein, as shown in formula The molar ratio of chalcone shown in (V), hydroxylamine hydrochloride shown in formula (VI), and pyridine is 1:3:6.
反应结束后,将反应体系自然冷却至室温,减压蒸馏除去溶剂得混合物,将混合物倒入1:1的水和乙酸乙酯中,萃取2-4次,收集有机相,用1mol/L的稀盐酸和饱和食盐水洗涤,MgSO4干燥,减压蒸馏旋干得到粗产品,将粗产物过200-300目硅胶柱色谱层析,以乙酸乙酯和石油醚混合液为洗脱剂,其中乙酸乙酯与石油醚的体积比1:10,从而得到为白色固体的所述式(II)化合物,熔点同实施例1,产率为83.3%。After the reaction, the reaction system was naturally cooled to room temperature, and the solvent was distilled off under reduced pressure to obtain a mixture. The mixture was poured into 1:1 water and ethyl acetate, extracted 2-4 times, and the organic phase was collected. Wash with dilute hydrochloric acid and saturated brine, dry over MgSO 4 , distill under reduced pressure and spin dry to obtain the crude product, the crude product is subjected to 200-300 mesh silica gel column chromatography, with ethyl acetate and petroleum ether mixed solution as eluent, wherein The volume ratio of ethyl acetate to petroleum ether was 1:10, thereby obtaining the compound of formula (II) as a white solid, the melting point of which was the same as that of Example 1, and the yield was 83.3%.
对比例1-24:碱的考察Comparative Example 1-24: Investigation of Alkali
对比例1-4:除分别将实施例1-4中的碱由吡啶替换为三乙胺外,其它操作均不变,而实施了对比例1-4。Comparative Example 1-4: Except that the base in Example 1-4 was replaced by triethylamine from pyridine, other operations were all unchanged, and Comparative Example 1-4 was implemented.
对比例5-8:除分别将实施例1-4中的碱由吡啶替换为碳酸钾,其它操作均不变,而实施了对比例5-8。Comparative Examples 5-8: Except that the bases in Examples 1-4 were replaced by potassium carbonate from pyridine, other operations were all unchanged, and Comparative Examples 5-8 were implemented.
对比例9-12:除分别将实施例1-4中的碱由吡啶替换为乙醇钠外,其它操作均不变,而实施了对比例9-12。Comparative Examples 9-12: Except that the bases in Examples 1-4 were replaced by sodium ethoxide from pyridine, other operations were all unchanged, and Comparative Examples 9-12 were implemented.
对比例13-16:除分别将实施例1-4中的碱由吡啶替换为叔丁醇钾外,其它操作均不变,而实施了对比例13-16。Comparative Examples 13-16: Except that the bases in Examples 1-4 were replaced by potassium tert-butoxide from pyridine, other operations were all unchanged, and Comparative Examples 13-16 were implemented.
对比例17-20:除分别将实施例1-4中的碱由吡啶替换为氢氧化钠外,其它操作均不变,而实施了对比例17-20。Comparative Examples 17-20: Except that the bases in Examples 1-4 were replaced by sodium hydroxide from pyridine, other operations were all unchanged, and Comparative Examples 17-20 were implemented.
对比例21-24:除分别将实施例1-4中的碱由吡啶替换为乙酸铵外,其它操作均不变,而实施了对比例21-24。Comparative Examples 21-24: Except that the bases in Examples 1-4 were replaced by ammonium acetate from pyridine, other operations were unchanged, and Comparative Examples 21-24 were implemented.
所得结果如表1所示。The obtained results are shown in Table 1.
表1:Table 1:
由此可见,其中碱的种类对产物产率有着显著影响,其中吡啶具有最好的效果,即便是与吡啶类似的三乙胺,其产率也有着显著的降低。This shows that wherein the type of base has a significant impact on the product yield, and wherein pyridine has the best effect, even if it is triethylamine similar to pyridine, its yield also has a significant reduction.
对比例25-32:溶剂的考察Comparative Examples 25-32: Investigation of Solvents
除将其中的溶剂由乙醇替换为如下的溶剂外,以与实施例1-4相同的方式而分别实施了对比例25-32,所使用溶剂、实施例对应关系和相应产物的收率如表2所示。Except that the solvent therein is replaced by the following solvent by ethanol, comparative examples 25-32 were implemented respectively in the same manner as in Examples 1-4, and the yields of the solvents used, the corresponding relationship of the examples and the corresponding products are shown in the table 2.
表2:Table 2:
由此可见,溶剂同样对最终结果有着一定的影响,其中EtOH具有最好的效果,即便是与其非常类似的MeOH,其产率也有一定程度的降低。It can be seen that the solvent also has a certain influence on the final result, among which EtOH has the best effect, even if it is very similar to MeOH, its yield is also reduced to a certain extent.
实施例5:Example 5:
向MeCN中,加入如式(Ⅱ)所示的查耳酮肟、如式(Ⅲ)所示的对甲苯磺酰基叠氮与如式(Ⅳ)所示的3-丁炔-2酮、醋酸亚铜(CuOAc)、三[(1-苄基-1H-1,2,3-三唑-4-基)甲基]胺(TBTA),然后升温至60℃,并在该温度下搅拌密封反应4小时;其中,式(Ⅱ)化合物、醋酸亚铜(CuOAc)、三[(1-苄基-1H-1,2,3-三唑-4-基)甲基]胺(TBTA)的摩尔比为1:0.1:0.1,式(II)化合物与式(III)化合物、式(IV)化合物的摩尔比为1:1.2:1.2,以及以毫摩尔计(mmol)计的式(II)化合物与以毫升(ml)计的MeCN的比为1:4。In MeCN, add chalcone oxime shown in formula (II), p-toluenesulfonyl azide shown in formula (III) and 3-butyne-2 ketone shown in formula (IV), acetic acid Cuprous (CuOAc), tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA), then heated to 60 °C, and stirred and sealed at this temperature Reaction for 4 hours; Wherein, formula (II) compound, cuprous acetate (CuOAc), three [(1-benzyl-1H-1,2,3-triazol-4-yl) methyl] amine (TBTA) The molar ratio is 1:0.1:0.1, the molar ratio of the compound of formula (II) to the compound of formula (III) and compound of formula (IV) is 1:1.2:1.2, and the formula (II) in millimoles (mmol) The ratio of compound to MeCN in milliliters (ml) was 1:4.
反应完全后,将反应体系自然冷却至室温,减压蒸馏除去溶剂得粗产物,将粗产物过200-300目硅胶柱色谱层析,以乙酸乙酯和石油醚混合液为洗脱剂,其中乙酸乙酯与石油醚的体积比1:5,从而得到为白色固体的目标产物式(I)化合物(C26H22N2O3S),产率为90.7%。After the reaction was complete, the reaction system was naturally cooled to room temperature, and the solvent was distilled off under reduced pressure to obtain a crude product. The crude product was subjected to 200-300 mesh silica gel column chromatography, using a mixture of ethyl acetate and petroleum ether as an eluent, wherein The volume ratio of ethyl acetate to petroleum ether was 1:5, so that the target compound of formula (I) (C 26 H 22 N 2 O 3 S) was obtained as a white solid with a yield of 90.7%.
熔点:202.8-204.4℃。Melting point: 202.8-204.4°C.
核磁共振:1HNMR(400MHz,DMSO-d6)δ12.64(s,1H),8.16(d,J=6.4Hz,2H),7.78(s,1H),7.71(d,J=8.2Hz,2H),7.52-7.46(m,3H),7.43-7.39(m,3H),7.37-7.34(m,2H),7.28-7.24(m,2H),2.45(s,3H),2.44(s,3H)。NMR: 1 HNMR (400MHz, DMSO-d 6 ) δ12.64(s, 1H), 8.16(d, J=6.4Hz, 2H), 7.78(s, 1H), 7.71(d, J=8.2Hz, 2H),7.52-7.46(m,3H),7.43-7.39(m,3H),7.37-7.34(m,2H),7.28-7.24(m,2H),2.45(s,3H),2.44(s, 3H).
13CNMR(100MHz,DMSO-d6)δ166.8,156.2,154.1,147.7,144.4,137.8,137.0,135.8,129.6(3C),128.8(2C),128.6,128.5(2C),128.1(3C),127.6(2C),127.0(2C),118.1,22.3,21.2。 ( _ 2C), 127.0 (2C), 118.1, 22.3, 21.2.
实施例6:Embodiment 6:
反应式同实施例5,具体操作为:Reaction formula is with embodiment 5, and concrete operation is:
向MeCN中,加入如式(Ⅱ)所示的查耳酮肟、如式(Ⅲ)所示的对甲苯磺酰基叠氮与如式(Ⅳ)所示的3-丁炔-2酮、醋酸亚铜(CuOAc)、三[(1-苄基-1H-1,2,3-三唑-4-基)甲基]胺(TBTA),然后升温至80℃,并在该温度下搅拌密封反应8小时;其中,式(Ⅱ)化合物、醋酸亚铜(CuOAc)、三[(1-苄基-1H-1,2,3-三唑-4-基)甲基]胺(TBTA)的摩尔比为1:0.2:0.2,式(II)化合物与式(III)化合物、式(IV)化合物的摩尔比为1:2:2,以及以毫摩尔计(mmol)计的式(II)化合物与以毫升(ml)计的MeCN的比为1:8。In MeCN, add chalcone oxime shown in formula (II), p-toluenesulfonyl azide shown in formula (III) and 3-butyne-2 ketone shown in formula (IV), acetic acid Cuprous (CuOAc), tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA), then heated to 80 °C, and stirred and sealed at this temperature Reaction for 8 hours; Wherein, formula (II) compound, cuprous acetate (CuOAc), three [(1-benzyl-1H-1,2,3-triazol-4-yl) methyl] amine (TBTA) The molar ratio is 1:0.2:0.2, the molar ratio of the compound of formula (II) to the compound of formula (III) and the compound of formula (IV) is 1:2:2, and the formula (II) in millimoles (mmol) The ratio of compound to MeCN in milliliters (ml) was 1:8.
反应完全后,将反应体系自然冷却至室温,减压蒸馏除去溶剂得粗产物,将粗产物过200-300目硅胶柱色谱层析,以乙酸乙酯和石油醚混合液为洗脱剂,其中乙酸乙酯与石油醚的体积比1:5,从而得到为白色固体的目标产物式(I)化合物(C26H22N2O3S),产率为87.5%。After the reaction was complete, the reaction system was naturally cooled to room temperature, and the solvent was distilled off under reduced pressure to obtain a crude product. The crude product was subjected to 200-300 mesh silica gel column chromatography, using a mixture of ethyl acetate and petroleum ether as an eluent, wherein The volume ratio of ethyl acetate to petroleum ether was 1:5, so that the target compound of formula (I) (C 26 H 22 N 2 O 3 S) was obtained as a white solid with a yield of 87.5%.
熔点及核磁共振数据同实施例5。Melting point and NMR data are the same as in Example 5.
实施例7:Embodiment 7:
反应式同实施例5,具体操作为:Reaction formula is with embodiment 5, and concrete operation is:
向MeCN中,加入如式(Ⅱ)所示的查耳酮肟、如式(Ⅲ)所示的对甲苯磺酰基叠氮与如式(Ⅳ)所示的3-丁炔-2酮、醋酸亚铜(CuOAc)、三[(1-苄基-1H-1,2,3-三唑-4-基)甲基]胺(TBTA),然后升温至90℃,并在该温度下搅拌密封反应2小时;其中,式(Ⅱ)化合物、醋酸亚铜(CuOAc)、三[(1-苄基-1H-1,2,3-三唑-4-基)甲基]胺(TBTA)的摩尔比为1:0.15:0.3,式(II)化合物与式(III)化合物、式(IV)化合物的摩尔比为1:1.5:1.5,以及以毫摩尔计(mmol)计的式(II)化合物与以毫升(ml)计的MeCN的比为1:6。In MeCN, add chalcone oxime shown in formula (II), p-toluenesulfonyl azide shown in formula (III) and 3-butyne-2 ketone shown in formula (IV), acetic acid Cuprous (CuOAc), tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA), then heated to 90 °C, and stirred and sealed at this temperature Reaction for 2 hours; Wherein, formula (II) compound, cuprous acetate (CuOAc), three [(1-benzyl-1H-1,2,3-triazol-4-yl) methyl] amine (TBTA) The molar ratio is 1:0.15:0.3, the molar ratio of the compound of formula (II) to the compound of formula (III) and the compound of formula (IV) is 1:1.5:1.5, and the formula (II) in millimoles (mmol) The ratio of compound to MeCN in milliliters (ml) was 1:6.
反应完全后,将反应体系自然冷却至室温,减压蒸馏除去溶剂得粗产物,将粗产物过200-300目硅胶柱色谱层析,以乙酸乙酯和石油醚混合液为洗脱剂,其中乙酸乙酯与石油醚的体积比1:5,从而得到为白色固体的目标产物式(I)化合物(C26H22N2O3S),产率为88.7%。After the reaction was complete, the reaction system was naturally cooled to room temperature, and the solvent was distilled off under reduced pressure to obtain a crude product. The crude product was subjected to 200-300 mesh silica gel column chromatography, using a mixture of ethyl acetate and petroleum ether as an eluent, wherein The volume ratio of ethyl acetate to petroleum ether was 1:5, so that the target compound of formula (I) (C 26 H 22 N 2 O 3 S) was obtained as a white solid with a yield of 88.7%.
熔点及核磁共振数据同实施例5。Melting point and NMR data are the same as in Example 5.
实施例8:Embodiment 8:
反应式同实施例5,具体操作为:Reaction formula is with embodiment 5, and concrete operation is:
向MeCN中,加入如式(Ⅱ)所示的查耳酮肟、如式(Ⅲ)所示的对甲苯磺酰基叠氮与如式(Ⅳ)所示的3-丁炔-2酮、醋酸亚铜(CuOAc)、三[(1-苄基-1H-1,2,3-三唑-4-基)甲基]胺(TBTA),然后升温至70℃,并在该温度下搅拌密封反应12小时;其中,式(Ⅱ)化合物、醋酸亚铜(CuOAc)、三[(1-苄基-1H-1,2,3-三唑-4-基)甲基]胺(TBTA)的摩尔比为1:0.25:0.5,式(II)化合物与式(III)化合物、式(IV)化合物的摩尔比为1:2.5:2.5,以及以毫摩尔计(mmol)计的式(II)化合物与以毫升(ml)计的MeCN的比为1:10。In MeCN, add chalcone oxime shown in formula (II), p-toluenesulfonyl azide shown in formula (III) and 3-butyne-2 ketone shown in formula (IV), acetic acid Cuprous (CuOAc), tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA), then heated to 70 °C, and stirred and sealed at this temperature Reaction for 12 hours; Wherein, formula (II) compound, cuprous acetate (CuOAc), three [(1-benzyl-1H-1,2,3-triazol-4-yl) methyl] amine (TBTA) The molar ratio is 1:0.25:0.5, the molar ratio of the compound of formula (II) to the compound of formula (III) and the compound of formula (IV) is 1:2.5:2.5, and the formula (II) in millimoles (mmol) The ratio of compound to MeCN in milliliters (ml) was 1:10.
反应完全后,将反应体系自然冷却至室温,减压蒸馏除去溶剂得粗产物,将粗产物过200-300目硅胶柱色谱层析,以乙酸乙酯和石油醚混合液为洗脱剂,其中乙酸乙酯与石油醚的体积比1:5,从而得到为白色固体的目标产物式(I)化合物(C26H22N2O3S),产率为89.6%。After the reaction was complete, the reaction system was naturally cooled to room temperature, and the solvent was distilled off under reduced pressure to obtain a crude product. The crude product was subjected to 200-300 mesh silica gel column chromatography, using a mixture of ethyl acetate and petroleum ether as an eluent, wherein The volume ratio of ethyl acetate to petroleum ether was 1:5, so that the target compound of formula (I) (C 26 H 22 N 2 O 3 S) was obtained as a white solid with a yield of 89.6%.
熔点及核磁共振数据同实施例5。Melting point and NMR data are the same as in Example 5.
对比例33-60:催化剂的考察Comparative Examples 33-60: Investigation of Catalysts
对比例33-36:除分别将实施例5-8中的催化剂由醋酸亚铜(CuOAc)替换为氯化亚铜(CuCl)外,其它操作均不变,而实施了对比例33-36。Comparative Examples 33-36: Except that the catalysts in Examples 5-8 were replaced by cuprous acetate (CuOAc) with cuprous chloride (CuCl), other operations were unchanged, and Comparative Examples 33-36 were implemented.
对比例37-40:除分别将实施例5-8中的催化剂由醋酸亚铜(CuOAc)替换为溴化铜(CuBr2)外,其它操作均不变,而实施了对比例37-40。Comparative Examples 37-40: Except that the catalysts in Examples 5-8 were replaced from cuprous acetate (CuOAc) to copper bromide (CuBr 2 ), other operations were unchanged, and Comparative Examples 37-40 were implemented.
对比例41-44:除分别将实施例5-8中的催化剂由醋酸亚铜(CuOAc)替换为三氟甲磺酸铜(Cu(OTf)2)外,其它操作均不变,而实施了对比例41-44。Comparative Examples 41-44: Except that the catalyst in Examples 5-8 is replaced by copper trifluoromethanesulfonate (Cu(OTf) 2 ) by cuprous acetate (CuOAc) respectively, other operations are all unchanged, and implemented Comparative Examples 41-44.
对比例45-48:除分别将实施例5-8中的催化剂由醋酸亚铜(CuOAc)替换为醋酸铜(Cu(OAc)2)外,其它操作均不变,而实施了对比例45-48。Comparative Examples 45-48: Except that the catalyst in Examples 5-8 is replaced by cuprous acetate (CuOAc) by copper acetate (Cu(OAc) 2 ), other operations are all unchanged, and comparative examples 45- 48.
对比例49-52:除分别将实施例5-8中的催化剂由醋酸亚铜(CuOAc)替换为噻吩-2-甲酸铜(CuTc)外,其它操作均不变,而实施了对比例49-52。Comparative example 49-52: except that the catalyst in embodiment 5-8 is replaced by cuprous acetate (CuOAc) by thiophene-2-formic acid copper (CuTc), other operation is all unchanged, and implements comparative example 49- 52.
对比例53-56:除分别将实施例5-8中的催化剂由醋酸亚铜(CuOAc)替换为氧化铜(CuO)外,其它操作均不变,而实施了对比例53-56。Comparative Examples 53-56: Except that the catalysts in Examples 5-8 were replaced from cuprous acetate (CuOAc) to copper oxide (CuO), other operations were unchanged, and Comparative Examples 53-56 were implemented.
对比例57-60:除分别将实施例5-8中的催化剂由醋酸亚铜(CuOAc)替换为碘化亚铜(CuI)外,其它操作均不变,而实施了对比例57-60。Comparative Examples 57-60: Except that the catalysts in Examples 5-8 were replaced from cuprous acetate (CuOAc) to cuprous iodide (CuI), other operations were unchanged, and Comparative Examples 57-60 were implemented.
所得结果如表3所示。The obtained results are shown in Table 3.
表3:table 3:
由此可见,催化剂的种类对产物产率有着显著影响,其中醋酸亚铜(CuOAc)或碘化亚铜(CuI)具有较好的催化效果,而醋酸亚铜则具有最好的催化性能,一价铜源的催化效果普遍比二价铜源的好,二价铜源的催化反应的产率降低至53.8-56.5%,甚至更低,已经失去了实际应用的价值。It can be seen that the type of catalyst has a significant impact on the product yield, and wherein cuprous acetate (CuOAc) or cuprous iodide (CuI) have a better catalytic effect, while cuprous acetate has the best catalytic performance. The catalytic effect of the valent copper source is generally better than that of the divalent copper source, and the yield of the catalytic reaction of the divalent copper source is reduced to 53.8-56.5%, or even lower, which has lost the value of practical application.
对比例61-68:配体的考察Comparative Examples 61-68: Examination of Ligands
除将其中的配体由三[(1-苄基-1H-1,2,3-三唑-4-基)甲基]胺(TBTA)换为如下的配体外,以与实施例5-8相同的方式而分别实施了对比例61-68,所使用配体、实施例对应关系和相应产物的收率如表2所示。Except that the ligand therein is changed from three [(1-benzyl-1H-1,2,3-triazol-4-yl) methyl]amine (TBTA) to the following ligand, in accordance with Example 5 In the same manner as in -8, comparative examples 61-68 were implemented respectively, and the ligands used, the corresponding relationship of the examples and the yield of the corresponding products are shown in Table 2.
表4:Table 4:
由此可见,在所有的配体中,三[(1-苄基-1H-1,2,3-三唑-4-基)甲基]胺(TBTA)或溶剂乙腈(不添加配体时,溶剂乙腈也是一种配体)具有合适的配位性,而其它配体则产率均有显著降低,甚至无法得到产物。此外,也可以看出,即便是与三[(1-苄基-1H-1,2,3-三唑-4-基)甲基]胺(TBTA)非常类似的三乙胺(Et3N)等三级胺,其配位效果也大幅度降低至28.4%,而其他具有强配位性的1,10-菲罗啉(Phen)等,则有着更为显著的降低,甚至不反应。It can be seen that among all the ligands, tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) or the solvent acetonitrile (when no ligand was added , solvent acetonitrile is also a kind of ligand) has suitable coordination property, and other ligands then productive rate all has remarkably reduced, even can't obtain product. Furthermore, it can also be seen that even triethylamine (Et 3 N ) and other tertiary amines, the coordination effect is also greatly reduced to 28.4%, while other strong coordination 1,10-phenanthroline (Phen), etc., have a more significant reduction, or even no reaction.
对比例69-76:溶剂的考察Comparative Examples 69-76: Investigation of Solvents
除将其中的溶剂由乙腈替换为如下的溶剂外,以与实施例5-8相同的方式而分别实施了对比例69-76,所使用溶剂、实施例对应关系和相应产物的收率如表5所示。Except that the solvent therein is replaced by the following solvent by acetonitrile, Comparative Examples 69-76 were respectively implemented in the same manner as in Examples 5-8, and the solvents used, the corresponding relationship of the examples and the yield of the corresponding products are shown in the table 5.
表5:table 5:
由此可见,溶剂同样对最终结果有着一定的影响,其中乙腈具有最好的效果,即便配位性是与其非常类似的DMF,其产率也有大幅度的降低。It can be seen that the solvent also has a certain influence on the final result, and acetonitrile has the best effect, even if the coordination property is very similar to DMF, its yield is also greatly reduced.
综上所述,由上述所有实施例可明确看出,当采用本发明的方法时,能够使式(II)化合物、式(III)化合物和式(IV)化合物顺利发生反应,从而得到目的产物,且产率良好、后处理简单,这些效果的取得,依赖于多个因素如催化剂、配体、溶剂的综合协同作用,当改变其中任何一个因素时都将导致产率显著降低。In summary, it can be clearly seen from all the above examples that when the method of the present invention is adopted, the compound of formula (II), the compound of formula (III) and the compound of formula (IV) can be reacted smoothly, thereby obtaining the target product , and the yield is good, and the post-treatment is simple. The achievement of these effects depends on the comprehensive synergy of multiple factors such as catalysts, ligands, and solvents. When any one of these factors is changed, the yield will be significantly reduced.
应当理解,这些实施例的用途仅用于说明本发明而非意欲限制本发明的保护范围。此外,也应理解,在阅读了本发明的技术内容之后,本领域技术人员可以对本发明作各种改动、修改和/或变型,所有的这些等价形式同样落于本申请所附权利要求书所限定的保护范围之内。It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the protection scope of the present invention. In addition, it should also be understood that after reading the technical content of the present invention, those skilled in the art can make various changes, modifications and/or variations to the present invention, and all these equivalent forms also fall within the appended claims of the present application. within the defined scope of protection.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910595185.8A CN110183378B (en) | 2019-07-03 | 2019-07-03 | Nicotinamide derivative and catalytic synthesis method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910595185.8A CN110183378B (en) | 2019-07-03 | 2019-07-03 | Nicotinamide derivative and catalytic synthesis method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110183378A true CN110183378A (en) | 2019-08-30 |
CN110183378B CN110183378B (en) | 2022-05-03 |
Family
ID=67724876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910595185.8A Active CN110183378B (en) | 2019-07-03 | 2019-07-03 | Nicotinamide derivative and catalytic synthesis method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110183378B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110483391A (en) * | 2019-09-17 | 2019-11-22 | 广东医科大学 | A kind of five component synthetic methods of nicotimine amide derivatives |
CN110483387A (en) * | 2019-09-17 | 2019-11-22 | 广东医科大学 | A kind of method of one pot process nicotimine amide derivatives |
CN113402476A (en) * | 2021-06-21 | 2021-09-17 | 广东湛江海洋医药研究院 | Imine oxazine derivative and preparation method thereof |
CN114315708A (en) * | 2022-02-07 | 2022-04-12 | 广东湛江海洋医药研究院 | Preparation method of 2-sulfamide pyridine derivative |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080182845A1 (en) * | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
CN103929956A (en) * | 2011-09-16 | 2014-07-16 | 拜耳知识产权有限责任公司 | Use of acylsulfonamides for improving plant yield |
CN105777727A (en) * | 2014-12-26 | 2016-07-20 | 沈阳中化农药化工研发有限公司 | 2-thiophene pyridine compound, and applications thereof |
-
2019
- 2019-07-03 CN CN201910595185.8A patent/CN110183378B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080182845A1 (en) * | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
CN103929956A (en) * | 2011-09-16 | 2014-07-16 | 拜耳知识产权有限责任公司 | Use of acylsulfonamides for improving plant yield |
CN105777727A (en) * | 2014-12-26 | 2016-07-20 | 沈阳中化农药化工研发有限公司 | 2-thiophene pyridine compound, and applications thereof |
Non-Patent Citations (4)
Title |
---|
PEI CHUI TOO, ET AL: "Rhodium(III)-catalyzed synthesis of pyridines from α,β-unsaturated ketoximes and internal alkynes", 《SYNLETT.》 * |
RAVI KUMAR, ET AL: "Cu-Catalyzed iminative hydroolefination of unactivated alkynes en route to 4-imino-tetrahydropyridines and 4-aminopyridines", 《CHEMICAL COMMUNICATIONS》 * |
RHIA M. MARTIN, ET AL: "Synthesis of Pyridines from Ketoximes and Terminal Alkynes via C-H Bond Functionalization", 《JOURNAL OF ORGANIC CHEMISTRY》 * |
彭文武,等: "Cu(OAc)2催化查尔酮肟酯与丁炔二酸二甲酯的环化反应合成多取代吡啶", 《安徽工程大学学报》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110483391A (en) * | 2019-09-17 | 2019-11-22 | 广东医科大学 | A kind of five component synthetic methods of nicotimine amide derivatives |
CN110483387A (en) * | 2019-09-17 | 2019-11-22 | 广东医科大学 | A kind of method of one pot process nicotimine amide derivatives |
CN110483391B (en) * | 2019-09-17 | 2022-09-30 | 广东医科大学 | Five-component synthesis method of nicotinamide amide derivative |
CN110483387B (en) * | 2019-09-17 | 2023-01-31 | 广东医科大学 | A kind of method for synthesizing nicotinamide derivatives in one pot |
CN113402476A (en) * | 2021-06-21 | 2021-09-17 | 广东湛江海洋医药研究院 | Imine oxazine derivative and preparation method thereof |
CN113402476B (en) * | 2021-06-21 | 2022-04-19 | 广东湛江海洋医药研究院 | Imine oxazine derivative and preparation method thereof |
CN114315708A (en) * | 2022-02-07 | 2022-04-12 | 广东湛江海洋医药研究院 | Preparation method of 2-sulfamide pyridine derivative |
CN114315708B (en) * | 2022-02-07 | 2023-02-17 | 广东湛江海洋医药研究院 | Preparation method of 2-sulfamide pyridine derivative |
Also Published As
Publication number | Publication date |
---|---|
CN110183378B (en) | 2022-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110183378B (en) | Nicotinamide derivative and catalytic synthesis method thereof | |
CN108033922B (en) | Preparation method of 3-acyl quinoxalinone derivative | |
CN105884698A (en) | Method for synthesizing diphenyl substituted quinazoline compound | |
CN110204474B (en) | Method for synthesizing tetra-substituted NH-pyrrole compound | |
CN110483387B (en) | A kind of method for synthesizing nicotinamide derivatives in one pot | |
CN108864164B (en) | A kind of synthetic method of primary amine-directed 2-alkynyl indole compounds | |
CN105949118A (en) | Preparation method of 2-aryl quinoline derivatives | |
CN113234015A (en) | 3-acyl dihydroquinoline derivative and preparation method and application thereof | |
CN109422700A (en) | A kind of synthetic method of N- acetyl group quinoxaline -2- amide and its derivative | |
CN109232529B (en) | Preparation method of Rh (III) catalytic compound with nitrogen heterocyclic skeleton | |
CN106892863A (en) | The preparation method of vismodegib and its intermediate | |
CN110483391B (en) | Five-component synthesis method of nicotinamide amide derivative | |
CN110294725B (en) | Derivative of sponge furanone and catalytic synthesis method thereof | |
CN104592006B (en) | A kind of synthetic method of phenylpropionic acid compound | |
CN104327025B (en) | A kind of preparation method of 4-arylnaphthalene lactone derivative | |
CN108558974B (en) | Preparation and Application of a Sugar-derived Pyridine Triazole Nickel Catalyst | |
CN106380469A (en) | Synthesis method of 1-aromatic carbonyl-2-aryl-3-ester imidazolone compounds | |
CN112409236B (en) | Method for synthesizing 3-thioether indole with high selectivity | |
CN113845481B (en) | Synthesis method of 4, 4-dimethyl-4, 5-dihydropyridazin-3-one | |
CN117229206B (en) | A method for preparing polysubstituted 2-quinolinone compounds by base catalysis | |
CN110283129A (en) | A method of synthesizing complete carbon-based substituted pyrimidines derivative | |
CN114478516B (en) | 3, 4-dihydro-2H-quinolizin-2-one compound and preparation method thereof | |
CN103864715B (en) | A method for catalytically synthesizing 2-acylbenzothiazole or derivatives thereof | |
CN114805360B (en) | A kind of preparation method of temozolomide | |
CN112538059B (en) | Reaction method for selectively synthesizing oxazole-4-carboxylic ester |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |